Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report

Clin Cosmet Investig Dermatol. 2023 Oct 9;16:2793-2800. doi: 10.2147/CCID.S419344. eCollection 2023.ABSTRACTCutaneous lupus erythematosus (CLE) is a group of diseases within the spectrum of lupus that primarily manifests with skin lesions. Discoid lupus erythematosus (DLE) is the most common subtype of CLE. Currently, there is no specific medication available for the treatment of CLE. Here, we reported the efficacy and safety of upadacitinib, a JAK1 selective inhibitor, in treating one DLE patient for 28 weeks. Upadacitinib 15mg QD alone improved DLE lesions significantly, while reduction of the drug to 15mg QOD led to a relapse of the skin lesions. Upadacitinib showed favorable safety in this DLE patient in the 28-week period, except for acne, which was controlled by topical application of benzoyl peroxide gel. In this case, we observed rapid and sustained improvement of DLE lesions using upadacitinib with favorable safety, which provided the opportunity to use upadacitinib as an alternative therapy for DLE.PMID:37841060 | PMC:PMC10573460 | DOI:10.2147/CCID.S419344
Source: Clinical, Cosmetic and Investigational Dermatology - Category: Dermatology Authors: Source Type: research